Full TitlePhase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification - Geometry-N
The purpose of this study is to assess the safety and effectiveness of the drug capmatinib in people with non-small cell lung cancer (NSCLC) that contains a mutation in a gene called MET and will be surgically removed. Capmatinib blocks the MET protein. When people have a mutation in the MET gene, the MET protein in cancer cells does not work properly, and it fails to stop those cells from growing. By blocking the MET protein, capmatinib may slow or stop cancer growth, and cancer cells may shrink.
In this study, participants will receive capmatinib before and after surgery. Capmatinib is currently used to treat metastatic NSCLC; its use in this study is considered investigational. Capmatinib is taken orally (by mouth).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have stage I-III NSLC that contains a MET mutation and will be surgically removed.
- Patients may not have received anticancer therapy for NSCLC within three years of entering the study.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Jamie Chaft at 646-608-3761.